Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune therapies—paired with MRD monitoring and intensified maintenance strategies—is ...

Artificial intelligence (AI) to speed diagnosis, the impact of switching complement therapies, the safety of ravulizumab during pregnancy, and iptacopan outcomes are among the insights into paroxysmal ...

Suchitra Sundaram, MD, shares that ASH 2025 presented major advances in chronic lymphocytic leukemia (CLL) across both time‑limited and continuous treatment strategies, and emphasized the growing role ...

Michael Wang, MD, highlights standout translational studies from ASH 2025 that advance understanding of prognosis and drug resistance in mantle cell lymphoma through epigenetic profiling and the ...

CURE was on site at the 2025 ASH Annual Meeting, sharing expert conversations and patient-focused reporting that highlighted progress in blood cancer care. The 2025 American Society of Hematology ...